background preloader

Nicotiana benthamiana

Facebook Twitter

Le site newcotiana_org. EUROPA_EU - Cordis Horizon 2020 - Developing Multipurpose Nicotiana Crops for Molecular Farming using New Plant Breeding Techniques. EN_WIKIPEDIA - Nicotiana benthamiana. Nicotiana benthamiana (colloquially known as benth or benthi) is a close relative of tobacco and species of Nicotiana indigenous to Australia.[1] The herbaceous plant is found amongst rocks on hills and cliffs throughout the northern regions of Australia. Variable in height and habit, the species may be erect and up to 1.5 metres (59.1 in) or sprawling out no taller than 200 millimetres (7.9 in).

The flowers are white.[2] The plant was used by people of Australia as a stimulant — it contains nicotine and other alkaloids — before the introduction of commercial tobacco (N. tabacum and N. rustica). N. benthamiana has been used as a model organism in plant research. N. benthamiana has a number of wild strains across Australia, and the laboratory strain is an extremophile originating from a population that has retained a loss-of-function mutation in Rdr1 (RNA-dependent RNA polymerase 1), rendering it hypersusceptible to viruses.[6] Nicotiana benthamiana, leaf.

Mol Plant Microbe Interact. 2008 Aug;21(8): Nicotiana benthamiana: its history and future as a model for plant-pathogen interactions. EUREKALERT 06/12/17 Tobacco plants as life-savers. Queensland University of Technology (QUT), Australia, is the sole international cooperation partner in an AUD$10.5 million European project to develop new tobacco varieties that can be used as biofactories for pharmaceuticals and vaccines.

Key points:QUT is one of 18 partners in the four-year Newcotiana project, and the only international collaborating partner QUT researchers' work sequencing the genome of Australian native tobacco plant Nicotiana benthamiana will underpin project research Newcotiana is funded by the European Commission through its Horizon2020 research and innovation program Research Fellow Dr Cara Mortimer, from QUT's Centre for Tropical Crops and Biocommodities, said the project aimed to develop an advanced 'toolbox' of plant breeding techniques for tobacco. These tools would be used to create high-value, non-smoking tobacco varieties to become factories producing molecules and proteins for life-saving drugs and vaccines.

Download video and images here. FRONT. PLANT SCI. 11/06/19 Production of Biopharmaceuticals in Nicotiana benthamiana—Axillary Stem Growth as a Key Determinant of Total Protein Yield. Introduction Several plants are used as heterologous expression hosts to produce recombinant proteins of medical interest, notably including the wild relative of tobacco Nicotiana benthamiana (Bally et al., 2018). This small plant from Australia presents a number of traits, such as a fast growth rate and a natural ability to express heterologous gene sequences, that make it particularly well suited to the production of biopharmaceuticals (Lomonossoff and D’Aoust, 2016). Efficient procedures have been devised for the transient expression of recombinant proteins in N. benthamiana that often involve the vacuum infiltration of leaf tissue with agrobacteria harboring a DNA transgene for the protein of interest delivered by either a viral replicon or a binary vector system (Leuzinger et al., 2013; Norkunas et al., 2018).

Our goal in this study was to document eventual relationships between cultural practices, host plant growth pattern and recombinant protein yield in N. benthamiana leaves. PLOS 03/12/10 Nicotiana benthamiana as a Production Platform for Artemisinin Precursors. Abstract Background Production of pharmaceuticals in plants provides an alternative for chemical synthesis, fermentation or natural sources. Nicotiana benthamiana is deployed at commercial scale for production of therapeutic proteins. Here the potential of this plant is explored for rapid production of precursors of artemisinin, a sesquiterpenoid compound that is used for malaria treatment. Methodology/Principal Findings Biosynthetic genes leading to artemisinic acid, a precursor of artemisinin, were combined and expressed in N. benthamiana by agro-infiltration. Conclusion/Significance This work shows that agroinfiltration of N. bentamiana can be used as a model to study the production of sesquiterpenoid pharmaceutical compounds.

Citation: van Herpen TWJM, Cankar K, Nogueira M, Bosch D, Bouwmeester HJ, Beekwilder J (2010) Nicotiana benthamiana as a Production Platform for Artemisinin Precursors. Editor: Haibing Yang, Purdue University, United States of America Introduction Figure 1. Results. JOURNAL DE MONTREAL 03/04/20 Des cigarettiers se posent en sauveurs. Des cigarettiers misent sur une plante de la famille du tabac pour développer un vaccin contre le coronavirus et c’est à Québec que la percée pourrait survenir. « On travaille avec une cousine du tabac, la nicotiana benthamiana, qui ne se fume pas », explique Jean-Luc Martre, vice-président au marketing chez Medicago.

L’entreprise intègre à cette plante des « particules pseudo-virales » qui permettent de fabriquer des vaccins. Medicago est détenue par le japonais Mitsubishi Tanabe (66 %) et le géant du tabac Philip Morris International (33 %). « Il s’agit d’un exemple de la rapidité avec laquelle la science et l’innovation peuvent obtenir des résultats positifs pour la société, peu importe qui finance les travaux », s’est félicité Philip Morris. Un autre grand cigarettier, BAT, propriétaire d’Imperial Tobacco, a annoncé mercredi qu’une de ses filiales travaillait également à un vaccin contre le coronavirus en recourant à un procédé semblable. Développement rapide Développement rapide. AFP 01/04/20 UN VACCIN CONTRE LE CORONAVIRUS UTILISANT DU TABAC DÉVELOPPÉ PAR UN CIGARETTIER. Le cigarettier British American Tobacco (BAT), qui fabrique les marques Lucky Strike et Dunhill entre autres, a annoncé mercredi qu'une de ses filiales travaillait sur un potentiel vaccin contre le coronavirus en utilisant des feuilles de tabac.

Le vaccin est en phase de test pré-clinique et n'a pas donc pas été testé sur l'homme n'a pas encore obtenu l'homologation des autorités sanitaires. Si son efficacité se confirmait, BAT afirme, avec l'aide de partenaires et des gouvernements, être en mesure de produire entre 1 et 3 millions de doses par semaine dès le mois de juin.

Sa filiale de bio-tech américaine, Kentucky BioProcessing (KBP), est parvenue à cloner un bout de la séquence du Covid-19 ce qui a permis de développer une molécule permettant de créer des anticorps à même de protéger contre le virus. Le groupe dit être déjà en contact avec les autorités sanitaires aux Etats-Unis et au Royaume-Uni.